DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced Chief Medical Officer Omar Manejwala, M.D. will present “Rebalancing: Digital Therapeutics in a Post-Pandemic Healthcare System” during the virtual conference DTx Europe on July 14th at 5:55 a.m. EST.
| NEW YORK, July 13, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced Chief Medical Officer Omar Manejwala, M.D. will present “Rebalancing: Digital Therapeutics in a Post-Pandemic Healthcare System” during the virtual conference DTx Europe on July 14th at 5:55 a.m. EST.  The theme for the DTx Europe 2021 virtual conference is Defining the Success of Digital Therapeutics. The event brings leaders of digital therapeutic companies, pharmaceutical companies, government and private health care entities to foster open discussion and learning opportunities. Dr. Manejwala’s presentation offers attendees perspective on the impacts of the pandemic going forward and guidance on leveraging digital therapeutics for maximum impact in a greatly changed healthcare ecosystem. “The increased adoption of digital therapeutics during the pandemic offered a promising view into the future of digital therapeutics as people successfully used these solutions to manage their health outside of the doctor’s office. As we resume more normal activities, the role of digital therapeutics should evolve so we can more effectively address outcomes and costs for a wide variety of conditions,” said Omar Manejwala, M.D., Chief Medical Officer, DarioHealth. To learn more about the conference and register for the live session, visit https://www.dtxeurope.com. About DarioHealth Corp. DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market - covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform. Dario’s next-generation, AI-powered, digital therapeutic platform supports more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software, and coaching to help individuals improve health and sustain meaningful outcomes. Dario’s unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results. The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and utilizes a performance-based approach to improve its users’ health. On the path to better health, Dario makes the right thing to do the easy thing to do. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com. DarioHealth Corporate Contact Suzanne Bedell Media Contact: Josephine Galatioto
SOURCE DarioHealth Corp. | ||
Company Codes: Stuttgart:LS1P, NASDAQ-SMALL:DRIO, Munich:LS1P, Berlin:LS1P |
View original content:
